In this online, self-learning activity:
The incidence of differentiated thyroid cancer (DTC) is on the rise over the past 10 years and roughly 57,000 new cases were reported in 2017 alone. Although the incidence of DTC has increased, the disease has a favorable prognosis with a reported 5-year survival rate of 98.2%. DTC can be categorized into two subcategories: papillary and follicular cancers. Collectively, these two thyroid cancer types account for 95% of all types of thyroid cancers. Diagnosis is typically made by palpating the central neck mass or through imaging studies, with ultrasound-guided fine-needle aspiration biopsy providing confirmation of diagnosis. However, not all cases of DTC require a biopsy, and certain types of DTC require molecular testing to properly classify the type of DTC. Patients with DTC often have genetic mutations, most notably in the MAPK and P13K/Akt/mTOR signaling pathways. The identification of these pathways has attracted considerable attention and research into the development of agents targeting them to inhibit their activity.
The following healthcare professionals: medical oncologists, endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with DTC.
Commercial Support Disclosure: This program is supported by educational grants from Eisai.
This activity is free of charge
Release Date: March 15, 2019 -- Expiration Date: March 15, 2021
Faculty: Beatrice Tendler, MD
Introduction content: cursory refresher and review
Treatment of DTC
By the end of the session the participant will be able to:
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Beatriz Tendler, M.D., Associate Professor, Endocrine Neoplasia, Clinic UCONN HEALTH, has no relevant financial discloses.
Disclosures of Educational Planners: Charles Turck, PharmD has no relevant financial discloses.
Commercial Support Disclosure: This program is supported by educational grants from Eisai
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Treating Oncology Patients During COVID-19
Metastatic Colon Cancer: Updates from the 2020 ASCO (American Society of Clinical Oncology) Annual Meeting
Advances in Treating Triple-Negative Metastatic Breast Cancer: Optimizing Pharmacotherapeutic Management Strategies